Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
Tóm tắt
To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer. Starting doses were gefitinib 250 mg/day orally without interruption, irinotecan 100 mg/m2 as a 90 min intravenous (i.v.) infusion, 5-FU 400 mg/m2 bolus i.v. and leucovorin 20 mg/m2 i.v. on days 1 and 8 of a 21-day cycle. Dose escalations involved increasing gefitinib to 500 mg then increasing irinotecan to 125 mg/m2 and 5-FU to 500 mg/m2. Twenty-four patients received therapy. The starting doses proved to be the MTD, as attempts to increase the dose of either gefitinib or the chemotherapeutic agents resulted in dose-limiting toxicities. Gastrointestinal effects and bone marrow suppression were the principal toxicities; however, only 1/17 (6%) patients treated with the MTD had severe (grades 3–4) diarrhea and severe neutropenia occurred in only two (12%) patients. Partial responses occurred in 10/17 patients receiving the MTD and another five had stable disease. Median progression-free and overall survivals were 12.2 and 26.6 months, respectively. In ten patients treated with the MTD, the steady-state PK of gefitinib was not affected by IFL nor did gefitinib appear to influence the PK of either irinotecan or 5-FU. Gefitinib can be safely combined with an intermittent weekly schedule of IFL. Evidence of promising activity should encourage further clinical evaluation of epidermal growth factor receptor tyrosine kinase inhibitors, such as gefitinib, combined with multiagent chemotherapy for metastatic colorectal cancer.
Tài liệu tham khảo
citation_journal_title=CA Cancer J Clin; citation_title=Cancer statistics, 2006; citation_author=A Jemal, R Siegel, E Ward, T Murray, J Xu, C Smigal; citation_volume=56; citation_issue=2; citation_publication_date=2006; citation_pages=106-130; citation_id=CR1
Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, et al (2003) SEER Cancer statistics review, 1975–2000. Institute NC, editor. Bethesda, MD, 2003. p. http://seer.cancer.gov/csr/1975_2000/
citation_journal_title=Expert Opin Investig Drugs; citation_title=Conventional cytotoxic and novel therapeutic concepts in colorectal cancer; citation_author=R Midgley, D Kerr; citation_volume=10; citation_issue=6; citation_publication_date=2001; citation_pages=1011-1019; citation_doi=10.1517/13543784.10.6.1011; citation_id=CR3
citation_journal_title=N Engl J Med; citation_title=Systemic therapy for colorectal cancer; citation_author=JA Meyerhardt, RJ Mayer; citation_volume=352; citation_issue=5; citation_publication_date=2005; citation_pages=476-487; citation_doi=10.1056/NEJMra040958; citation_id=CR4
citation_journal_title=Clin Cancer Res; citation_title=Blockade of receptors for growth factors: an anticancer therapy—the fourth annual Joseph H Burchenal American association of cancer research clinical research award lecture; citation_author=J Mendelson; citation_volume=6; citation_issue=3; citation_publication_date=2000; citation_pages=747-753; citation_id=CR5
citation_journal_title=Cancer; citation_title=The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer; citation_author=A Mayer, M Takimoto, E Fritz, G Schellander, K Kofler, H Ludwig; citation_volume=71; citation_issue=8; citation_publication_date=1993; citation_pages=2454-2460; citation_doi=10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; citation_id=CR6
citation_journal_title=Crit Rev Oncol Hematol; citation_title=Epidermal growth factor-related peptides and their receptors in human malignancies; citation_author=DS Salomon, R Brandt, F Ciardiello, N Normanno; citation_volume=19; citation_issue=3; citation_publication_date=1995; citation_pages=183-232; citation_doi=10.1016/1040-8428(94)00144-I; citation_id=CR7
citation_journal_title=J Surg Oncol; citation_title=Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67; citation_author=AW Hemming, NL Davis, A Kluftinger, B Robinson, NF Quenville, B Liseman; citation_volume=51; citation_issue=3; citation_publication_date=1992; citation_pages=147-152; citation_doi=10.1002/jso.2930510304; citation_id=CR8
citation_journal_title=N Engl J Med; citation_title=Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer; citation_author=D Cunningham, Y Humblet, S Siena, D Khayat, H Bleiberg, A Santoro; citation_volume=351; citation_issue=4; citation_publication_date=2004; citation_pages=337-345; citation_doi=10.1056/NEJMoa033025; citation_id=CR9
citation_journal_title=Proc Am Soc Clin Oncol; citation_title=Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR); citation_author=L Saltz, M Rubin, H Hochster, NS Tchekmeydian, H Waksal, M Needle; citation_volume=20; citation_publication_date=2001; citation_pages=3a; citation_id=CR10
citation_journal_title=J Clin Oncol; citation_title=Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor; citation_author=LB Saltz, NJ Meropol, PJ Loehrer, MN Needle, J Kopit, RJ Mayer; citation_volume=22; citation_issue=7; citation_publication_date=2004; citation_pages=1201-1208; citation_doi=10.1200/JCO.2004.10.182; citation_id=CR11
citation_journal_title=Proc Am Soc Clin Oncol; citation_title=Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer; citation_author=I Malik, JR Hecht, A Patnaik, A Venook, J Berlin, G Croghan; citation_volume=23; citation_issue=16S; citation_publication_date=2005; citation_pages=3520; citation_id=CR12
citation_journal_title=Proc Am Soc Clin Oncol; citation_title=ZD1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer; citation_author=O Dorligschaw, T Kegel, K Jordan, A Harba, A Grothey, H-J Schmoll; citation_volume=23; citation_publication_date=2003; citation_pages=1494; citation_id=CR13
citation_journal_title=J Clin Oncol; citation_title=Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies; citation_author=M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto; citation_volume=19; citation_issue=13; citation_publication_date=2001; citation_pages=3267-3279; citation_id=CR14
citation_journal_title=Clin Colorectal Cancer; citation_title=Epidermal growth factor receptor in not correlated with prognosis in patients with metastatic colorectal cancer treated with erlotinib (OSI-774, Tarceva); citation_author=M Hightower, J Klem, D Lee; citation_volume=3; citation_issue=1; citation_publication_date=2003; citation_pages=10-11; citation_id=CR15
citation_journal_title=J Clin Oncol; citation_title=Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer; citation_author=T Kuo, CD Cho, J Halsey, HA Wakelee, RH Advani, JM Ford; citation_volume=23; citation_issue=24; citation_publication_date=2005; citation_pages=5613-5619; citation_doi=10.1200/JCO.2005.08.359; citation_id=CR16
citation_journal_title=J Clin Oncol; citation_title=Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer; citation_author=JA Meyerhardt, AX Zhu, PC Enzinger, DP Ryan, JW Clark, MH Kulke; citation_volume=24; citation_issue=12; citation_publication_date=2006; citation_pages=1892-1897; citation_doi=10.1200/JCO.2005.05.3728; citation_id=CR17
citation_journal_title=Anticancer Drugs; citation_title=The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan; citation_author=AH Braun, K Stark, O Dirsch, RA Hilger, S Seeber, U Vanhoefer; citation_volume=16; citation_issue=10; citation_publication_date=2005; citation_pages=1099-1108; citation_doi=10.1097/00001813-200511000-00009; citation_id=CR18
citation_journal_title=Int J Cancer; citation_title=Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (“Iressa”) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells; citation_author=F Koizumi, F Kanzawa, Y Ueda, Y Koh, S Tsukiyama, F Taguchi; citation_volume=108; citation_issue=3; citation_publication_date=2004; citation_pages=464-472; citation_doi=10.1002/ijc.11539; citation_id=CR19
citation_journal_title=Cancer Res; citation_title=Gefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance; citation_author=Y Nakamura, M Oka, H Soda, K Shiozawa, M Yoshikawa, A Itoh; citation_volume=65; citation_issue=4; citation_publication_date=2005; citation_pages=1541-1546; citation_doi=10.1158/0008-5472.CAN-03-2417; citation_id=CR20
citation_journal_title=Cancer Res; citation_title=Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice; citation_author=CF Stewart, M Leggas, JD Schuetz, JC Panetta, PJ Cheshire, J Peterson; citation_volume=64; citation_issue=20; citation_publication_date=2004; citation_pages=7491-7499; citation_doi=10.1158/0008-5472.CAN-04-0096; citation_id=CR21
citation_journal_title=J Natl Cancer Inst; citation_title=New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada; citation_author=P Therasse, SG Arbuck, EA Eisenhauer, J Wanders, RS Kaplan, L Rubinstein; citation_volume=92; citation_issue=3; citation_publication_date=2000; citation_pages=205-216; citation_doi=10.1093/jnci/92.3.205; citation_id=CR22
Institute NC (2006) Common terminology criteria for adverse events (CTCAE) version 2.0. Cited 14 July 2006
citation_journal_title=J Liq Chromatogr; citation_title=Determination of gefitinib in plasma by liquid chromatography with a C12 column and electrospray tandem mass spectrometry detection; citation_author=F Bai, L Iacono, B Johnston; citation_volume=27; citation_publication_date=2004; citation_pages=2743-2758; citation_doi=10.1081/JLC-200029312; citation_id=CR24
citation_journal_title=Clin Cancer Res; citation_title=Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma; citation_author=MR Gilbert, JG Supko, T Batchelor, G Lesser, JD Fisher, S Piantadosi; citation_volume=9; citation_issue=8; citation_publication_date=2003; citation_pages=2940-2949; citation_id=CR25
citation_journal_title=Cancer Res; citation_title=Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea; citation_author=E Gupta, TM Lestingi, R Mick, J Ramirez, EE Vokes, MJ Ratain; citation_volume=54; citation_issue=14; citation_publication_date=1994; citation_pages=3723-3725; citation_id=CR26
citation_journal_title=Clin Colorectal Cancer; citation_title=Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer; citation_author=AX Zhu, TA Puchalski, VP Stanton, DP Ryan, JW Clark, S Nesbitt; citation_volume=3; citation_issue=4; citation_publication_date=2004; citation_pages=225-234; citation_doi=10.3816/CCC.2004.n.003; citation_id=CR27
citation_journal_title=Pharm Sci Technol Today; citation_title=Methodology for pharmacokinetic/pharmacodynamic data analysis; citation_author=JL Gabrielsson, DL Weiner; citation_volume=2; citation_issue=6; citation_publication_date=1999; citation_pages=244-252; citation_doi=10.1016/S1461-5347(99)00162-5; citation_id=CR28
citation_title=Pharmacokinetics, ; citation_publication_date=1982; citation_id=CR29; citation_author=M Gibaldi; citation_author=D Perrier; citation_publisher=Marcel Dekker
citation_journal_title=Chem Pharm Bull (Tokyo); citation_title=Preparation of mean drug concentration—time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters; citation_author=E Mizuta, A Tsubotani; citation_volume=33; citation_issue=4; citation_publication_date=1985; citation_pages=1620-1632; citation_id=CR30
citation_journal_title=J Biopharm Stat; citation_title=Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed?; citation_author=LF Lacey, ON Keene, JF Pritchard, A Bye; citation_volume=7; citation_issue=1; citation_publication_date=1997; citation_pages=171-178; citation_doi=10.1080/10543409708835177; citation_id=CR31
citation_journal_title=Biometrika; citation_title=The jacknife—a review; citation_author=R Miller; citation_volume=61; citation_publication_date=1974; citation_pages=1-15; citation_id=CR32
citation_journal_title=J Clin Oncol; citation_title=Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma; citation_author=JL Grem, N McAtee, RF Murphy, JM Hamilton, F Balis, S Steinberg; citation_volume=12; citation_issue=3; citation_publication_date=1994; citation_pages=560-568; citation_id=CR33
citation_journal_title=J Clin Oncol; citation_title=Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors; citation_author=LB Saltz, J Kanowitz, NE Kemeny, L Schaaf, D Spriggs, BA Staton; citation_volume=14; citation_issue=11; citation_publication_date=1996; citation_pages=2959-2967; citation_id=CR34
citation_journal_title=J Clin Oncol; citation_title=Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients; citation_author=E Gupta, R Mick, J Ramirez, X Wang, TM Lestingi, EE Vokes; citation_volume=15; citation_issue=4; citation_publication_date=1997; citation_pages=1502-1510; citation_id=CR35
citation_journal_title=J Clin Oncol; citation_title=Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel; citation_author=ML Rothenberg, NJ Meropol, EA Poplin, E Cutsem, S Wadler; citation_volume=19; citation_issue=18; citation_publication_date=2001; citation_pages=3801-3807; citation_id=CR36
citation_journal_title=Semin Oncol; citation_title=Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?; citation_author=RM Goldberg; citation_volume=25; citation_issue=5 Suppl 11; citation_publication_date=1998; citation_pages=21-28; citation_id=CR37
citation_journal_title=Oncology (Huntingt); citation_title=Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule; citation_author=JJ Hwang, SG Eisenberg, JL Marshall; citation_volume=17; citation_issue=9 Suppl 8; citation_publication_date=2003; citation_pages=37-43; citation_id=CR38
citation_journal_title=J Clin Oncol ASCO Annu Meet Proc; citation_title=N9741: FOLFOX (oxaliplatin(Oxal)/5-fluorouracil (5-FU)/leucovorin (LV) or reduced dose R-IFL (CPT-11 + 5-FU/LV) in advanced colorectal cancer (CRC): final efficacy data from an intergroup study; citation_author=RM Goldberg, DJ Sargent, RF Morton, C Fuchs, RK Ramanathan, SK Williamson; citation_volume=22; citation_issue=14S; citation_publication_date=2004; citation_pages=3621; citation_id=CR39
citation_journal_title=N Engl J Med; citation_title=Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group; citation_author=LB Saltz, JV Cox, C Blanke, LS Rosen, L Fehrenbacher, MJ Moore; citation_volume=343; citation_issue=13; citation_publication_date=2000; citation_pages=905-914; citation_doi=10.1056/NEJM200009283431302; citation_id=CR40
citation_journal_title=J Clin Oncol; citation_title=Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial; citation_author=RS Herbst, AM Maddox, ML Rothenberg, EJ Small, EH Rubin, J Baselga; citation_volume=20; citation_issue=18; citation_publication_date=2002; citation_pages=3815-3825; citation_doi=10.1200/JCO.2002.03.038; citation_id=CR41
citation_journal_title=J Clin Oncol; citation_title=ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial; citation_author=M Ranson, LA Hammond, D Ferry, M Kris, A Tullo, PI Murray; citation_volume=20; citation_issue=9; citation_publication_date=2002; citation_pages=2240-2250; citation_doi=10.1200/JCO.2002.10.112; citation_id=CR42
citation_journal_title=Br J Cancer; citation_title=A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer; citation_author=ML Veronese, W Sun, B Giantonio, J Berlin, J Shults, L Davis; citation_volume=92; citation_issue=10; citation_publication_date=2005; citation_pages=1846-1849; citation_doi=10.1038/sj.bjc.6602569; citation_id=CR43
citation_journal_title=Clin Pharmacokinet; citation_title=Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol; citation_author=HC Swaisland, M Ranson, RP Smith, J Leadbetter, A Laight, D McKillop; citation_volume=44; citation_issue=10; citation_publication_date=2005; citation_pages=1067-1081; citation_doi=10.2165/00003088-200544100-00005; citation_id=CR44
citation_journal_title=Xenobiotica; citation_title=Cytochrome P450-dependent metabolism of gefitinib; citation_author=D McKillop, AD McCormick, A Millar, GS Miles, PJ Phillips, M Hutchison; citation_volume=35; citation_issue=1; citation_publication_date=2005; citation_pages=39-50; citation_doi=10.1080/00498250400026464; citation_id=CR45
citation_journal_title=J Natl Cancer Inst; citation_title=Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes; citation_author=RH Mathijssen, FA Jong, RH Schaik, ER Lepper, LE Friberg, T Rietveld; citation_volume=96; citation_issue=21; citation_publication_date=2004; citation_pages=1585-1592; citation_id=CR46
citation_journal_title=Drug Metab Dispos; citation_title=Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino) carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan; citation_author=K Fujita, Y Ando, M Narabayashi, T Miya, F Nagashima, W Yamamoto; citation_volume=33; citation_issue=12; citation_publication_date=2005; citation_pages=1785-1790; citation_id=CR47
citation_journal_title=J Clin Oncol; citation_title=Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer; citation_author=VA Miller, DH Johnson, LM Krug, B Pizzo, L Tyson, W Perez; citation_volume=21; citation_issue=11; citation_publication_date=2003; citation_pages=2094-2100; citation_doi=10.1200/JCO.2003.12.008; citation_id=CR48
citation_journal_title=Clin Lung Cancer; citation_title=A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer; citation_author=C Manegold, U Gatzemeier, E Buchholz, RP Smith, A Fandi; citation_volume=6; citation_issue=6; citation_publication_date=2005; citation_pages=343-349; citation_doi=10.3816/CLC.2005.n.013; citation_id=CR49
citation_journal_title=Annu Rev Med; citation_title=The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents; citation_author=EK Rowinsky; citation_volume=48; citation_publication_date=1997; citation_pages=353-374; citation_doi=10.1146/annurev.med.48.1.353; citation_id=CR50
citation_journal_title=J Natl Cancer Inst; citation_title=FDA Oncology Committee debates Iressa’s status following negative trial results; citation_author=R Twombly; citation_volume=97; citation_issue=7; citation_publication_date=2005; citation_pages=473; citation_id=CR51
citation_journal_title=J Natl Cancer Inst; citation_title=Failing survival advantage in crucial trial, future of Iressa is in jeopardy; citation_author=R Twombly; citation_volume=97; citation_issue=4; citation_publication_date=2005; citation_pages=249-250; citation_doi=10.1093/jnci/97.4.249; citation_id=CR52